Testing two antifungal drugs for mucormycosis with blood cancer
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed blood cancer such as leukemia, lymphoma, or myelodysplastic syndrome.
- You must have a definite, likely, or possible diagnosis of mucormycosis (a fungal infection).
- You must be between 18 and 65 years old.
- You must be well enough to carry out daily activities (ECOG score 0-2).
- Your major organs (kidneys, liver, heart) must be working well enough for the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests antifungal drugs in people with a rare but serious fungal infection in the lungs called mucormycosis. It aims to find which treatment works best and is safest for patients.
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
This study looks for specific lab “biomarkers” in people with mucormycosis, a serious fungal infection. It compares results with people who have higher infection risk but no active infection, to help doctors diagnose and track this illness more accurately.
This trial tests amphotericin B (an antifungal medication) in patients with blood cancers who develop a fungal infection despite already taking antifungal preventive medicine. The study aims to see if this medication can treat these hard-to-treat infections.
This trial tests a new drug, S241656, alone or with other treatments, for people with specific types of blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have not responded to standard treatments or have come back.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
Hear when a new Mucormycosis in Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.